Biotech | October 27, 2021
Novavax files for approval of its Covid-19 vaccine in the UK
Filing marks first protein-based vaccine submitted to MHRA for authorization
Filing marks first protein-based vaccine submitted to MHRA for authorization
Cipla has reported consolidated financial results for the period ended September 30, 2021
FDI increased 98% year on year in 2020 and pharma exports grew by 18% in the last financial year
Expands wound care portfolio and aims to drive greater market penetration and availability in the wound dressing category
Strengthens supply chain continuity with first manufacturing facility outside of the U.S.
The Research Services and Biosimilars business segments reported a growth of 17% and 10%, respectively
Key takeaways of recent quarter & conference call highlights
Key takeaways of recent quarter & conference call highlights
The company is continuing with the evaluation of canakinumab in lung cancer, and is applying findings to the overall lung cancer development plan
The company’s wide therapeutic portfolio helped to sustain growth despite changing market demand
Subscribe To Our Newsletter & Stay Updated
